FDA Approval Pushes Dermira’s Stock Price Up
Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age. After this announcement, Dermira rose around 5.6% in the morning trading. Dermira estimates that almost 15 million people in the United States suffer from hyperhidrosis, of which 10 million suffer from axillary hyperhidrosis.